# Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

> **NCT04076579** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 29 (actual)

## Conditions studied

- Sarcoma
- Sarcoma Metastatic

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Trabectedin

## Key facts

- **NCT ID:** NCT04076579
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-17
- **Primary completion:** 2023-01-30
- **Final completion:** 2024-09-26
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-08-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04076579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04076579, "Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04076579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*